File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma

TitleInsulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma
Authors
Keywordsflow cytometry
insulin-like growth factor
tumor cell-cycle proliferation
Issue Date1995
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescie
Citation
Life Sciences, 1995, v. 56 n. 10, p. 747-756 How to Cite?
AbstractThis study was designed to determine whether intravenous infusion of recombinant human insulin-like growth factor 1 (IGF-1) stimulates tumor growth. In order to determine the potential interaction between nutrition and IGF-1 administration the study was conducted in fasting rats and during continuous feeding by total parenteral nutrition. Tumor cell cycle kinetics including labeling index, DNA synthesis time, cell cycle time in G0/G1, and G2/M in the total cell cycle, and potential doubling time were determined by flow cytometry after in vivo pulse labeling the rats bearing the Walker-256 Carcinosarcoma with 5'-bromo-2'-deoxyuridine (BrdUrd). The results show that IGF-1 treatment has no significant effects on the proliferative characteristics of the tumor model regardless of the feeding status of the animal. This study provides preliminary cell-cycle kinetics data on the short-term effect of IGF-1 on tumor growth. Failure to show a significant effect of IGF-1 on the proliferative characteristics of the tumor suggests that IGF-1 may be given to cancer patients in amounts sufficient to promote weight gain without deleterious stimulation of tumor proliteration.
Persistent Identifierhttp://hdl.handle.net/10722/178572
ISSN
2021 Impact Factor: 6.780
2020 SCImago Journal Rankings: 1.131
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWan, JMFen_US
dc.contributor.authorIstfan, NWen_US
dc.contributor.authorYe, SLen_US
dc.contributor.authorBistrian, BRen_US
dc.date.accessioned2012-12-19T09:48:28Z-
dc.date.available2012-12-19T09:48:28Z-
dc.date.issued1995en_US
dc.identifier.citationLife Sciences, 1995, v. 56 n. 10, p. 747-756en_US
dc.identifier.issn0024-3205en_US
dc.identifier.urihttp://hdl.handle.net/10722/178572-
dc.description.abstractThis study was designed to determine whether intravenous infusion of recombinant human insulin-like growth factor 1 (IGF-1) stimulates tumor growth. In order to determine the potential interaction between nutrition and IGF-1 administration the study was conducted in fasting rats and during continuous feeding by total parenteral nutrition. Tumor cell cycle kinetics including labeling index, DNA synthesis time, cell cycle time in G0/G1, and G2/M in the total cell cycle, and potential doubling time were determined by flow cytometry after in vivo pulse labeling the rats bearing the Walker-256 Carcinosarcoma with 5'-bromo-2'-deoxyuridine (BrdUrd). The results show that IGF-1 treatment has no significant effects on the proliferative characteristics of the tumor model regardless of the feeding status of the animal. This study provides preliminary cell-cycle kinetics data on the short-term effect of IGF-1 on tumor growth. Failure to show a significant effect of IGF-1 on the proliferative characteristics of the tumor suggests that IGF-1 may be given to cancer patients in amounts sufficient to promote weight gain without deleterious stimulation of tumor proliteration.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescieen_US
dc.relation.ispartofLife Sciencesen_US
dc.subjectflow cytometry-
dc.subjectinsulin-like growth factor-
dc.subjecttumor cell-cycle proliferation-
dc.subject.meshAnimalsen_US
dc.subject.meshBromodeoxyuridine - Metabolismen_US
dc.subject.meshCarcinoma 256, Walker - Pathologyen_US
dc.subject.meshCell Cycleen_US
dc.subject.meshCell Divisionen_US
dc.subject.meshDna - Biosynthesisen_US
dc.subject.meshFastingen_US
dc.subject.meshFlow Cytometryen_US
dc.subject.meshInsulin-Like Growth Factor I - Pharmacologyen_US
dc.subject.meshKineticsen_US
dc.subject.meshMaleen_US
dc.subject.meshParenteral Nutrition, Totalen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Sprague-Dawleyen_US
dc.subject.meshRecombinant Proteins - Pharmacologyen_US
dc.titleInsulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcomaen_US
dc.typeArticleen_US
dc.identifier.emailWan, JMF: jmfwan@hku.hken_US
dc.identifier.authorityWan, JMF=rp00798en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0024-3205(95)00005-Qen_US
dc.identifier.pmid7885190-
dc.identifier.scopuseid_2-s2.0-0028891681en_US
dc.identifier.volume56en_US
dc.identifier.issue10en_US
dc.identifier.spage747en_US
dc.identifier.epage756en_US
dc.identifier.isiWOS:A1995QD54300005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWan, JMF=8930305000en_US
dc.identifier.scopusauthoridIstfan, NW=7003819779en_US
dc.identifier.scopusauthoridYe, SL=7202088340en_US
dc.identifier.scopusauthoridBistrian, BR=35463916700en_US
dc.identifier.issnl0024-3205-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats